DREADDs
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Amisulpride (HB1879)
Description:Potent, selective dopamine D2 and D3 receptor antagonist. Atypical antipsychotic.
Purity:>98%
-
Bromocriptine mesylate (HB1813)
Description:Potent, selective D2-like receptor agonist
Purity:>98%
-
Olanzapine (HB1786)
Description:5-HT2A and D2 antagonist. Potent DREADD agonist. Atypical antipsychotic.
Purity:>99%
-
Prochlorperazine dimaleate (HB1907)
Description:D2 receptor antagonist. Also 5-HT3 and nAChR antagonist.
Purity:>99%
-
Quetiapine hemifumarate (HB1803)
Description:5-HT2 and D2 antagonist. Atypical antipsychotic.
Purity:>99%
-
Ziprasidone hydrochloride (HB1753)
Description:5-HT2A and D2 antagonist. Atypical antipsychotic.
Purity:>99%
-
Zotepine (HB1778)
Description:5-HT2A and dopamine D2 receptor antagonist. Atypical antipsychotic.
Purity:>99%
